Ottobock SE & Co. KGaA is a German medical technology company based in Duderstadt, specializing in orthopedic solutions such as prosthetics, orthotics, wheelchairs, and exoskeletons. Founded in 1919 by Otto Bock in Berlin, the company develops, manufactures, and distributes medical technology products aimed at individuals with disabilities. Its market presence spans Europe, the Middle East, Africa, the Americas, and the Asia Pacific region. Key products include the C-Leg, a microprocessor-controlled knee joint; C-Brace, a computer-controlled leg orthosis; Bebionic Hand, a multi-articulating prosthetic hand; Juvo Power Wheelchairs, designed for better mobility; and Paexo Exoskeletons, which promote ergonomic work environments. As of 2025, Ottobock reported revenues of €1.6 billion and employed approximately 9,300 people across 45 countries. Majority ownership belongs to Näder Holding GmbH & Co. KG, a family-owned business. The company went public on October 9, 2025, listing its shares on the Deutsche Börse Xetra under the ticker symbol OBCK, with an initial offering price between €62 and €66 per share. Additionally, Ottobock has been a partner of the Paralympics since 1988, highlighting its commitment to improving mobility and independence for people with disabilities.
AI-researched from public web sources, not from the exchange listing itself — may contain errors or omissions and is not a substitute for verifying independently.
Ottobock SE & Co. KGaA's offering is currently approved on OTHER. Ottobock SE & Co. KGaA is headquartered in Germany. It is classified under Biotech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Ottobock SE & Co. KGaA.
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/ottobock-se-co-kgaa" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Ottobock SE & Co. KGaA — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/ottobock-se-co-kgaa?theme=light as the src instead.
https://www.discoveripo.com/ipo/ottobock-se-co-kgaa/opengraph-image
Ottobock SE & Co. KGaA IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/ottobock-se-co-kgaa?utm_source=embed&utm_medium=text&utm_campaign=ottobock-se-co-kgaa
Get emailed when Ottobock SE & Co. KGaA's terms, price, or expected date change — no weekly noise, just this company.
Ottobock SE & Co. KGaA is listing on OTHER.
Ottobock SE & Co. KGaA is a German medical technology company based in Duderstadt, specializing in orthopedic solutions such as prosthetics, orthotics, wheelchairs, and exoskeletons. Founded in 1919 by Otto Bock in Berlin, the company develops, manufactures, and distributes medical technology products aimed at individuals with disabilities. Its market presence spans Europe, the Middle East, Africa, the Americas, and the Asia Pacific region. Key products include the C-Leg, a microprocessor-controlled knee joint; C-Brace, a computer-controlled leg orthosis; Bebionic Hand, a multi-articulating prosthetic hand; Juvo Power Wheelchairs, designed for better mobility; and Paexo Exoskeletons, which promote ergonomic work environments. As of 2025, Ottobock reported revenues of €1.6 billion and employed approximately 9,300 people across 45 countries. Majority ownership belongs to Näder Holding GmbH & Co. KG, a family-owned business. The company went public on October 9, 2025, listing its shares on the Deutsche Börse Xetra under the ticker symbol OBCK, with an initial offering price between €62 and €66 per share. Additionally, Ottobock has been a partner of the Paralympics since 1988, highlighting its commitment to improving mobility and independence for people with disabilities.
European Securities and Markets Authority's Prospectus Regulation register — a prospectus approval date, not a confirmed listing date. Retrieved Aug 26, 2026.
View the original filing on ESMA →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy